Edition:
United Kingdom

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

32.05USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$32.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
84,630
52-wk High
$37.20
52-wk Low
$16.45

Chart for

About

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $842.90
Shares Outstanding(Mil.): 30.82
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc will wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.

13 Dec 2017

BRIEF-Revance Announces Pricing Of Public Offering Of Common Stock

* REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

07 Dec 2017

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

* REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: (http://bit.ly/2nwJNaw) Further company coverage:

05 Dec 2017

BRIEF-Revance Announces Proposed Public Offering Of Common Stock

* REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

05 Dec 2017

BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials

* REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES

05 Dec 2017

BRIEF-Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia

* REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA

29 Nov 2017

BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

* Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

20 Nov 2017

BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01

* Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​

02 Nov 2017

BRIEF-Revance completes patient enrollment in Phase 2 program for RT002 injectable

* Revance completes patient enrollment in Phase 2 program for RT002 injectable in the management of plantar fasciitis

18 Oct 2017

BRIEF-Revance Q2 ‍loss per share $0.90​

* Revance Therapeutics Inc - ‍reaffirmed its financial guidance provided in January 2017​

03 Aug 2017

Earnings vs. Estimates